Ambrx Biopharma Inc. (AMAM) |
|
2.37 0.02 (0.85%)
|
08-07 23:31 |
|
Open: |
2.35 |
Pre. Close: |
2.35 |
|
High:
|
2.4699 |
Low:
|
2.36 |
|
Volume:
|
12,057 |
Market Cap:
|
91(M) |
|
|
|
|
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.47 - 2.49 |
2.49 - 2.5 |
|
Low:
|
2.33 - 2.35 |
2.35 - 2.36 |
|
Close:
|
2.35 - 2.37 |
2.37 - 2.4 |
|
Technical analysis |
as of: 2022-08-05 4:20:06 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.32 One year: 3.69 |
| Support: |
Support1: 2.32 Support2: 1.93 |
| Resistance: |
Resistance1: 2.84 Resistance2: 3.16 |
| Pivot: |
2.66  |
| Moving Average: |
MA(5): 2.42 MA(20): 2.69
MA(100): 3.59 MA(250): 7.55 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 8 %D(3): 6.2 |
| RSI: |
RSI(14): 31.6 |
| 52-week: |
High: 18.86 Low: 2.32 |
| Average Vol(K): |
3-Month: 10 (K) 10-Days: 11 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AMAM ] has closed above bottom band by 10.8%. Bollinger Bands are 0.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sat, 06 Aug 2022
CWC Challenge League A 2022, Match 15: VAN vs SIN Dream11 Prediction, Fantasy Cricket Tips, Playing 11, Pitch Report and Injury Update - CricTracker
Thu, 21 Jul 2022
Critical Comparison: Ambrx Biopharma (NYSE:AMAM) & Fate Therapeutics (NASDAQ:FATE) - Defense World
Wed, 06 Jul 2022
Ambrx (AMAM) Appoints Edward Hu and Kate Hermans to its Board - StreetInsider.com
Fri, 06 May 2022
Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences - Business Wire
Fri, 29 Apr 2022
Win a round at St. Andrews in Westport Open AmAm 2022 - Connaught Telegraph
Tue, 26 Apr 2022
Ambrx Biopharma Inc. (AMAM) Q4 2021 Earnings Call Transcript - The Motley Fool
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
39 (M) |
| Shares Float |
14 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
51 (%) |
|
Shares Short
|
4 (K) |
|
Shares Short P.Month
|
8 (K) |
Stock Financials |
|
EPS
|
-3.33 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.92 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-857.3 |
|
Return on Assets (ttm)
|
-22 |
|
Return on Equity (ttm)
|
-42.3 |
|
Qtrly Rev. Growth
|
-67.7 |
|
Gross Profit (p.s.)
|
0.19 |
|
Sales Per Share
|
0.19 |
|
EBITDA (p.s.)
|
-1.61 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-45 (M) |
|
Levered Free Cash Flow
|
-21 (M) |
Stock Valuations |
|
PE Ratio
|
-0.72 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.48 |
|
Price to Sales
|
12.25 |
|
Price to Cash Flow
|
-2.05 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
